Phase I study of teclistamab, a humanized B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed/refractory multiple myeloma (R/R MM).

被引：32
作者：
Usmani, Saad Zafar
Mateos, Maria-Victoria
Nahi, Hareth
Krishnan, Amrita Y.
van de Donk, Niels W. C. J.
San Miguel, Jesus
Oriol, Albert
Rosinol, Laura
Chari, Ajai
Adams, Homer
Girgis, Suzette
Lin, Shun Xin Wang
Stephenson, Tara
Kemmerer, Kristy
Smit, Jennifer
Elsayed, Yusri A.
Infante, Jeffrey R.
Goldberg, Jenna D.
Banerjee, Arnob
Garfall, Alfred L.
机构：
[1] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA
[2] Univ Hosp Salamanca IBSAL, Salamanca, Spain
[3] Karolinska Inst, Stockholm, Sweden
[4] Karolinska Univ Hosp Huddinge, Stockholm, Sweden
[5] City Hope Natl Med Ctr, Duarte, CA USA
[6] Vrije Univ Amsterdam Med Ctr, Amsterdam Univ, Med Ctr, Amsterdam, Netherlands
[7] Clin Univ Navarra, Pamplona, Spain
[8] Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Badalona, Spain
[9] Hosp Badalona Germans Trias & Pujol, Inst Josep Carreras, Badalona, Spain
[10] Hosp Clin Barcelona, Barcelona, Spain
[11] Mt Sinai Sch Med, Dept Hematol Oncol, New York, NY USA
[12] Janssen Res & Dev LLC, Spring House, PA USA
[13] Janssen Res & Dev LLC, Raritan, NJ USA
[14] Perelman Sch Med, Philadelphia, PA USA
[15] Abramson Canc Ctr, Philadelphia, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
10.1200/JCO.2020.38.15_suppl.100
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
100
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Updated phase 1 results of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM).
    Krishnan, Amrita Y.
    Garfall, Alfred L.
    Mateos, Maria-Victoria
    van de Donk, Niels W. C. J.
    Nahi, Hareth
    San-Miguel, Jesus F.
    Oriol, Albert
    Rosinol, Laura
    Chari, Ajai
    Bhutani, Manisha
    Karlin, Lionel
    Benboubker, Lotfi
    Pei, Lixia
    Verona, Raluca
    Girgis, Suzette
    Stephenson, Tara
    Goldberg, Jenna D.
    Banerjee, Arnob
    Usmani, Saad Zafar
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM)
    Garfall, Alfred L.
    Usmani, Saad Z.
    Mateos, Maria-Victoria
    Nahi, Hareth
    van de Donk, Niels W. C. J.
    San-Miguel, Jesus F.
    Rocafiguera, Albert Oriol
    Rosinol, Laura
    Chari, Ajai
    Bhutani, Manisha
    Pei, Lixia
    Verona, Raluca
    Girgis, Suzette
    Stephenson, Tara
    Goldberg, Jenna D.
    Banerjee, Arnob
    Krishnan, Amrita
    BLOOD, 2020, 136
  • [3] Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC-1
    Cortes-Selva, Diana
    Casneuf, Tineke
    Vishwamitra, Deeksha
    Stein, Sarah
    Perova, Tatiana
    Skerget, Sheri
    Ramos, Elena
    van Steenbergen, Laure
    De Maeyer, Dries
    Boominathan, Rengasamy
    Lau, Onsay
    Davis, Cuc
    Banerjee, Arnob
    Stephenson, Tara
    Uhlar, Clarissa M.
    Kobos, Rachel
    Goldberg, Jenna D.
    Pei, Lixia
    Trancucci, Danielle
    Girgis, Suzette
    Lin, Shun Xin Wang
    Wu, Liviawati S.
    Moreau, Philippe
    Usmani, Saad
    Bahlis, Nizar Jacques
    Van de Donk, Niels W. C. J.
    Verona, Raluca
    BLOOD, 2022, 140
  • [4] Initial safety results for MagnetisMM-3: A phase 2 trial of elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients (pts) with relapsed/refractory (R/R) multiple myeloma (MM).
    Lesokhin, Alexander M.
    Arnulf, Bertrand
    Niesvizky, Ruben
    Mohty, Mohamad
    Bahlis, Nizar J.
    Tomasson, Michael H.
    Rodriguez-Otero, Paula
    Quach, Hang
    Raje, Noopur S.
    Iida, Shinsuke
    Raab, Marc-Steffen
    Czibere, Akos
    Sullivan, Sharon
    Leip, Eric
    Viqueira, Andrea
    Leleu, Xavier
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] A Phase 1/2 study of teclistamab, a humanized BCMA x CD3 bispecific Ab in Japanese patients with relapsed/refractory MM
    Ishida, Tadao
    Kuroda, Yoshiaki
    Matsue, Kosei
    Komeno, Takuya
    Ishiguro, Takuro
    Ishikawa, Jun
    Ito, Toshiro
    Kosugi, Hiroshi
    Sunami, Kazutaka
    Nishikawa, Kazuko
    Shibayama, Kazuhiro
    Aida, Kensuke
    Yamazaki, Hiroshi
    Inagaki, Mitsuo
    Kobayashi, Hisanori
    Iida, Shinsuke
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2025, 121 (02) : 222 - 231
  • [6] Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM).
    Bahlis, Nizar J.
    Raje, Noopur S.
    Costello, Caitlin
    Dholaria, Bhagirathbhai R.
    Solh, Melhem M.
    Levy, Moshe Y.
    Tomasson, Michael H.
    Dube, Harman
    Liu, Feng
    Liao, Kai Hsin
    Basu, Cynthia
    Skoura, Athanasia
    Chan, Edward Michael
    Trudel, Suzanne
    Jakubowiak, Andrzej J.
    Chu, Michael P.
    Gasparetto, Cristina
    Dalovisio, Andrew
    Sebag, Michael
    Lesokhin, Alexander M.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [7] Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma
    Moreau, Philippe
    Usmani, Saad Z.
    Garfall, Alfred L.
    van de Donk, Niels W. C. J.
    Nahi, Hareth
    San-Miguel, Jesus
    Oriol, Albert
    Nooka, Ajay K.
    Martin, Thomas
    Rosino, Laura
    Chari, Ajai
    Karlin, Lionel
    Benboubker, Lotfi
    Mateos, Maria-Victoria
    Bahlis, Nizar J.
    Popat, Rakesh
    Besemer, Britta
    Martínez-López, Joaquín
    Sidana, Surbhi
    Pei, Lixia
    Trancucci, Danielle
    Verona, Raluca I.
    Girgis, Suzette
    Olyslager, Yunsi
    Jaffe, Mindy
    Uhlar, Clarissa M.
    Stephenson, Tara
    Van Rampelbergh, Rian
    Banerjee, Arnob
    Goldberg, Jenna D.
    Kobos, Rachel
    Krishnan, Amrita Y.
    BLOOD, 2021, 138
  • [8] Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): Updated efficacy and safety results from MajesTEC-1.
    Nooka, Ajay K.
    Moreau, Philippe
    Usmani, Saad Zafar
    Garfall, Alfred L.
    Van De Donk, Niels W. C. J.
    San-Miguel, Jesus F.
    Oriol Rocafiguera, Albert
    Chari, Ajai
    Karlin, Lionel
    Mateos, Maria-Victoria
    Popat, Rakesh
    Martinez, Joaquin
    Sidana, Surbhi
    Trancucci, Danielle
    Verona, Raluca
    Girgis, Suzette
    Uhlar, Clarissa
    Stephenson, Tara
    Banerjee, Arnob
    Krishnan, Amrita Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [9] Updated Results From the Phase 1/2 MajesTEC-1 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma
    Popat, Rakesh
    Usmani, Saad Z.
    Garfall, Alfred
    van de Donk, Niels
    Nahi, Hareth
    San-Miguel, Jesus F.
    Oriol, Albert
    Nooka, Ajay
    Martin, Thomas
    Rosinol, Laura
    Chari, Ajai
    Karlin, Lionel
    Benboubker, Lotfi
    Mateos, Maria-Victoria
    Bahlis, Nizar
    Moreau, Philippe
    Besemer, Britta
    Martinez-Lopez, Joaquin
    Sidana, Surbhi
    Pei, Lixia
    Trancucci, Danielle
    Verona, Raluca
    Girgis, Suzette
    Olyslager, Yunsi
    Jaffe, Mindy
    Uhlar, Clarissa
    Stephenson, Tara
    Van Rampelbergh, Rian
    Banerjee, Arnob
    Goldberg, Jenna D.
    Kobos, Rachel
    Krishnan, Amrita
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 35 - 36
  • [10] Efficacy and safety of teclistamab (tec), a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients (pts) with relapsed/refractory multiple myeloma (RRMM) after exposure to other BCMA-targeted agents.
    Touzeau, Cyrille
    Krishnan, Amrita Y.
    Moreau, Philippe
    Perrot, Aurore
    Usmani, Saad Zafar
    Manier, Salomon
    Cavo, Michele
    Martinez-Chamorro, Carmen
    Nooka, Ajay K.
    Martin, Thomas G.
    Karlin, Lionel
    Leleu, Xavier
    Bahlis, Nizar J.
    Besemer, Britta
    Pei, Lixia
    Verona, Raluca
    Girgis, Suzette
    Uhlar, Clarissa
    Kobos, Rachel
    Garfall, Alfred L.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345